- Home
- MURA vs APLT Comparison
MURA vs APLT Comparison
Compare MURA & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MURA
- APLT
- Stock Information
- Founded
- MURA 2013
- APLT 2016
- Country
- MURA Ireland
- APLT United States
- Employees
- MURA N/A
- APLT N/A
- Industry
- MURA
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- MURA
- APLT Health Care
- Exchange
- MURA Nasdaq
- APLT Nasdaq
- Market Cap
- MURA 45.8M
- APLT 37.5M
- IPO Year
- MURA N/A
- APLT 2019
- Fundamental
- Price
- MURA $2.64
- APLT $0.36
- Analyst Decision
- MURA Strong Buy
- APLT Buy
- Analyst Count
- MURA 4
- APLT 7
- Target Price
- MURA $13.00
- APLT $6.10
- AVG Volume (30 Days)
- MURA 190.3K
- APLT 2.7M
- Earning Date
- MURA 05-14-2025
- APLT 05-13-2025
- Dividend Yield
- MURA N/A
- APLT N/A
- EPS Growth
- MURA N/A
- APLT N/A
- EPS
- MURA N/A
- APLT N/A
- Revenue
- MURA N/A
- APLT $265,000.00
- Revenue This Year
- MURA $34.35
- APLT $1,768.13
- Revenue Next Year
- MURA N/A
- APLT $332.85
- P/E Ratio
- MURA N/A
- APLT N/A
- Revenue Growth
- MURA N/A
- APLT N/A
- 52 Week Low
- MURA $0.95
- APLT $0.30
- 52 Week High
- MURA $4.74
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- MURA 51.30
- APLT 42.18
- Support Level
- MURA $2.56
- APLT $0.37
- Resistance Level
- MURA $2.72
- APLT $0.40
- Average True Range (ATR)
- MURA 0.15
- APLT 0.06
- MACD
- MURA -0.02
- APLT -0.01
- Stochastic Oscillator
- MURA 31.37
- APLT 3.72
About MURA Mural Oncology plc
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.